# Hong Kong’s First PIC/S GMP-Certified Stem Cell Production Facility Established at Science Park

- Link: https://www.thailand-business-news.com/pr-news/hong-kongs-first-pic-s-gmp-certified-stem-cell-production-facility-established-at-science-park
- Published: 2026-07-31T15:20:00+07:00
- Author: Media OutReach

#### _HKSTP Hosts Showcase Featuring Clinical Progress from 10 Park Companies and Real-Life Patient Stories_

HONG KONG SAR – [Media OutReach Newswire](https://www.media-outreach.com) – 31 July
2026 – Hong Kong Science and Technology Parks Corporation (HKSTP) today hosted the
HKSTP Cell and Gene Therapy (CGT) Showcase 2026 at the Charles K. Kao Auditorium,
Hong Kong Science Park, with support from Invest Hong Kong. The event brought together
more than 200 representatives from the healthcare, academic, investment and regulatory
sectors, both locally and from overseas. A major milestone announced at the event
was that HKSTP partner company Hong Kong Regen Medtech Limited (HKRM) has become
the first facility in Hong Kong to be recognised by the Pharmacy and Poisons Board
of Hong Kong (PPBHK) as an allogeneic mesenchymal stem cell (MSC) PIC/S GMP manufacturing
facility, enabling the production of advanced therapy products for clinical trials.

![HKSTP hosted the HKSTP CGT Showcase 2026, bringing together local and overseas
I&T enterprises, medical experts, researchers, investors and patient representatives
to explore the clinical translation and broader development of cell and gene therapy.](
https://images.media-outreach.com/release.php/Thumb/1600x1066/793186/793186-P1-jpg-
1600x1066.jpeg)

 _HKSTP hosted the HKSTP CGT Showcase 2026, bringing together local and overseas
I&T enterprises, medical experts, researchers, investors and patient representatives
to explore the clinical translation and broader development of cell and gene therapy._

 Mr Terry Wong, CEO of HKSTP, said in his remarks: “Cell and gene therapy is one
of the fastest-growing fields in life and health tech. The establishment of Hong
Kong’s first stem cell production facility certified to PIC/S GMP standards at Hong
Kong Science Park marks a significant milestone for the city’s life and health tech
ecosystem. The significance of this certification goes far beyond technology alone.
It signifies not only that production has met the highest international safety standards,
but also that patients and their families can choose locally manufactured cell therapy
products with confidence and complete trust. This is a tangible achievement that
will enable every Hong Kong citizen to benefit directly. As the orchestrator of 
Hong Kong’s innovation and technology (I&T) ecosystem, HKSTP has been proactively
connecting the life and health tech community with partners, investors and academia.
Through a diverse range of incubation programmes, we provide our park companies 
with seed funding, innovation space, world-class infrastructure and regulatory support,
helping them overcome challenges in the journey from laboratory research to clinical
translation and turning scientific breakthroughs into real therapeutic outcomes 
for patients. We will continue to drive ecosystem development and fully support 
local I&T enterprises in bringing research achievements ‘Made in Hong Kong’ to the
global stage.”

 **Hong Kong’s First PIC/S GMP Stem Cell Production Facility Bridges a Critical 
Gap from Research to Clinical Application**

 One of the highlights of the event was HKRM, an HKSTP partner company, recently
obtaining Hong Kong’s first PIC/S GMP licence for stem cell production and operating
the related manufacturing facility at Hong Kong Science Park, marking a key step
in advancing the clinical translation of advanced therapies in Hong Kong. PIC/S 
GMP is internationally recognised as the gold standard for pharmaceutical manufacturing
quality. Facilities must undergo rigorous international assessment to ensure that
every batch is produced in a strictly controlled environment.

 Mr Stanley Sy, HKRM Co-founder and CEO, said: “HKRM’s attainment of Hong Kong’s
first PIC/S GMP certification for stem cell production marks not only an important
milestone in the company’s development, but also signifies that Hong Kong now has
the critical infrastructure needed to further support the clinical translation of
advanced cell therapies. A stringent, internationally recognised manufacturing quality
system helps ensure product consistency and traceability, while strengthening the
confidence of medical and regulatory authorities in locally manufactured cell-based
products. Based at Hong Kong Science Park, HKRM is grateful for the longstanding
support of HKSTP. We also look forward to working with research and clinical partners
in the Park to bring more promising therapeutic solutions from Hong Kong to the 
international stage.”

 **Patients, Families and Doctors Share First-hand Stories of the Journey from Cell
Banking to Clinical Breakthroughs**

 The event also featured first-hand experiences from patients, their families and
doctors on their treatment journeys. Park company Mononuclear Therapeutics (MonoTx)
operates Hong Kong’s first AABB-accredited public cord blood bank and haematopoietic
stem cell apheresis facility at Hong Kong Science Park, with more than 2,000 cord
blood units in storage.

 Dr Wendy Cheng, Chief Operating Officer of MonoTx, joined Professor Leung Tak Yeung
and Professor Ronald Wang of the Department of Obstetrics and Gynaecology at The
Chinese University of Hong Kong (CUHK) to share research findings and patient cases
with patient families.

 Professor Leung Tak Yeung’s team at CUHK is studying a treatment for foetuses with
severe alpha-thalassaemia by processing the mother’s stem cells through MonoTx and
infusing them into the foetus, to investigate whether the foetus can develop immune
tolerance to the mother’s stem cells and thereby improve clinical outcomes.

 Professor Ronald Wang’s team is using cord blood to treat neonatal brain injury.
Preliminary findings suggest that cord blood infusion within 48 hours of birth may
help repair brain injury and improve the child’s developmental outcomes later in
life.

 **360 Life Sciences Companies Gather at Hong Kong Science Park, Reinforcing Hong
Kong’s Position as an International Health and Medical Innovation Hub**

 Hong Kong Science Park is home to more than 360 life sciences companies, while 
the number of cell and gene therapy (CGT) enterprises continues to grow, spanning
frontier fields such as stem cells, gene editing, personalised cancer vaccines and
CAR-T immunotherapy, and addressing diseases including cancer, heart failure and
neurodegenerative disorders. HKSTP will continue to strengthen Hong Kong’s position
as an international health and medical innovation hub by accelerating the translation
and application of more locally developed R&D outcomes for the benefit of patients,
the industry and society. In doing so, it aims to make innovative therapies more
accessible and enable Hong Kong to play an even greater role on the global life 
and health tech stage.

Hashtag: #HKSTP

The issuer is solely responsible for the content of this announcement.

#### Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001
to create a thriving I&T ecosystem grooming 14 unicorns, more than 17,000 research
professionals and over 2,400 technology companies from 26 countries and regions 
focused on developing healthtech, AI and robotics, fintech and smart city technologies,
etc.

 Our growing innovation ecosystem offers comprehensive support to attract and nurture
talent, accelerate and commercialise innovation for technology ventures, with the
I&T journey built around our key locations of Hong Kong Science Park in Pak Shek
Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan
O and Yuen Long realising a vision of new industrialisation for Hong Kong, where
sectors including advanced manufacturing, micro-electronics and biotechnology are
being reimagined.

 Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles
in connecting the world and the mainland with our proximity, strengthening cross-
border exchange to bring advantages in attracting global talent and allowing possibilities
for the development of technology companies in seven key areas: Medtech, big data
and AI, robotics, new materials, microelectronics, fintech and sustainability, with
both dry and wet laboratories, co-working space, conference and exhibition facilities,
and more.

 Through our R&D infrastructure, startup support and enterprise services, commercialisation
and investment expertise, partnership networks and talent traction, HKSTP continues
to contribute in establishing I&T as a pillar of growth for Hong Kong.

 More information about HKSTP is available at [www.hkstp.org](https://apc01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.hkstp.org%2F&data=05%7C02%7Cjuly.wu%40hkstp.org%7C063bee05e6a542e2363808deeed1d734%7Cb3e19ac2e19244c890bd41acbfb3dcdb%7C0%7C0%7C639210784787724521%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=AdC%2FBm55qoyspG92z0lTDYXm6F40ok%2BT6OLr3uX8SlY%3D&reserved=0).

![](//track.media-outreach.com/index.php/WebView/479033/36955)

**Source** : [Hong Kong’s First PIC/S GMP-Certified Stem Cell Production Facility Established at Science Park](https://www.media-outreach.com/news/hong-kong-sar/2026/07/31/479033/?rand=186006)

---

  |  This article was produced by Media OutReach, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not reflect the opinions of Thailand Business News. |

---

![Media OutReach Newswire](https://i0.wp.com/www.thailand-business-news.com/wp-content/
uploads/2025/04/media-outreach-20025.png?ssl=1)
